ERBB2 and triple-negative breast carcinoma: Since higher rates of triple-negative breast cancer and human epidermal growth factor type 2 (HER2)-positive subtypes were detected in patients with AYA breast cancer, 55.5% of patients have received chemotherapy, including neoadjuvant chemotherapy (Kataoka et al., 2014).